Coverage, Pre-Symptomatic Care, and Non-Insulin Users: Expanding CGM's Role

This episode, titled 'Coverage, Pre-Symptomatic Care, and Non-Insulin Users: Expanding CGM's Role,' features diabetes and managed care experts discussing the following critical questions:

1. The ADA states that access should continue regardless of A1C levels. How does this shift the conversation for coverage of CGM devices?
2. How can clinicians prepare and adapt for a future managing pre-symptomatic type 1 diabetes with CGM technology?
3. For patients who are on non-insulin medication who may benefit from CGM, how do you frame the conversation about cost and adherence? What metrics resonate most with this population?

Led by the moderator, Estay Greene and Victoria Bouhairie examined the limitations of A1C as a sole measure of diabetes control, noting that a patient can appear well-managed by A1C while still experiencing dangerous glucose variability, hypoglycemia, or significant post-meal spikes, making the shift toward time in range a critical evolution in how coverage and treatment decisions are made. The discussion also explored how early screening and CGM use in pre-symptomatic type 1 diabetes patients can reduce diabetic ketoacidosis (DKA) risk, enabling a proactive rather than reactive approach to care. The experts further addressed the value of CGM for non-insulin users, framing its benefits around personalized lifestyle insights and real-time engagement that can drive meaningful behavioral change and long-term complication reduction.
Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.
In the next episode, 'ADA Accommodations and CGM Device Types: A Closer Look,' panelists will continue their discussion on diabetes and highlight the ADA's recommended accommodations for CGM use across schools, workplaces, and hospitals, as well as the distinctions between real-time, intermittent scanning, over-the-counter, and professional CGM devices.